Q4 EPS Forecast for Ionis Pharmaceuticals Reduced by Analyst

Ionis Pharmaceuticals, Inc. (NASDAQ:IONS – Free Report) – Equities researchers at HC Wainwright cut their Q4 2027 earnings estimates for Ionis Pharmaceuticals in a research note issued to investors on Tuesday, November 10th. HC Wainwright analyst M. Kapoor now expects that the company will post earnings of $0.14 per share for the quarter, down from their prior estimate of $0.19. HC Wainwright has a “Buy” rating and a $70.00 price target on the stock. The consensus estimate for Ionis Pharmaceuticals’ current full-year earnings is ($3.57) per share.

Ionis Pharmaceuticals (NASDAQ:IONS – Get Free Report) last posted its quarterly earnings results on Monday, November 9th. The company reported ($0.66) earnings per share (EPS) for the quarter, topping the consensus estimate of ($1.23) by $0.57. Ionis Pharmaceuticals had a negative net margin of 56.98% and a negative return on equity of 120.62%. The firm had revenue of $242.72 million for the quarter, compared to analyst estimates of $178.17 million. During the same period in the prior year, the firm posted ($0.80) earnings per share. The company’s quarterly revenue was up 54.8% compared to the same quarter last year.

IONS has been the subject of several other reports. JPMorgan Chase & Co. cut their target price on shares of Ionis Pharmaceuticals from $76.00 to $70.00 and set an “overweight” rating for the company in a research note on Tuesday, September 22nd. Barclays lowered their price target on Ionis Pharmaceuticals from $90.00 to $85.00 and set an “overweight” rating on the stock in a research report on Wednesday, September 9th. UBS Group started coverage on Ionis Pharmaceuticals in a research note on Thursday, October 15th. They issued a “buy” rating and a $88.00 price objective on the stock. Weiss Ratings cut Ionis Pharmaceuticals from a “sell (d-)” rating to a “sell (e+)” rating in a research report on Monday. Finally, Royal Bank Of Canada cut their price objective on Ionis Pharmaceuticals from $85.00 to $60.00 and set an “outperform” rating for the company in a research report on Tuesday, November 10th. Nineteen equities research analysts have rated the stock with a Buy rating, three have assigned a Hold rating and one has given a Sell rating to the company’s stock. According to MarketBeat.com, the company currently has an average rating of “Moderate Buy” and a consensus target price of $75.00.

Check Out Our Latest Report on IONS

Ionis Pharmaceuticals Stock Up 1.6%

Shares of IONS stock opened at $27.39 on Thursday. The company has a debt-to-equity ratio of 3.42, a quick ratio of 5.36 and a current ratio of 5.43. The firm’s 50-day moving average is $41.88 and its 200-day moving average is $63.74. The stock has a market cap of $4.56 billion, a price-to-earnings ratio of -8.25 and a beta of 0.43. Ionis Pharmaceuticals has a 52-week low of $26.55 and a 52-week high of $86.74.

Institutional Inflows and Outflows

Several large investors have recently bought and sold shares of the stock. Virtu Financial LLC acquired a new stake in Ionis Pharmaceuticals during the third quarter worth approximately $483,000. Allworth Financial LP boosted its holdings in shares of Ionis Pharmaceuticals by 537.6% during the third quarter. Allworth Financial LP now owns 3,290 shares of the company’s stock worth $147,000 after acquiring an additional 2,774 shares during the period. Quantitative Investment Management LLC acquired a new position in shares of Ionis Pharmaceuticals in the third quarter valued at approximately $423,000. Quarry LP grew its position in shares of Ionis Pharmaceuticals by 6,796.6% in the third quarter. Quarry LP now owns 2,000 shares of the company’s stock valued at $89,000 after purchasing an additional 1,971 shares during the last quarter. Finally, Aquatic Capital Management LLC grew its position in shares of Ionis Pharmaceuticals by 39.9% in the third quarter. Aquatic Capital Management LLC now owns 59,561 shares of the company’s stock valued at $2,659,000 after purchasing an additional 16,980 shares during the last quarter. 93.86% of the stock is owned by institutional investors.

Insider Buying and Selling at Ionis Pharmaceuticals

In other news, EVP Shannon L. Devers sold 1,357 shares of the firm’s stock in a transaction dated Friday, October 16th. The shares were sold at an average price of $43.54, for a total transaction of $59,083.78. Following the completion of the sale, the executive vice president owned 17,811 shares in the company, valued at approximately $775,490.94. This trade represents a 7.08% decrease in their position. The transaction was disclosed in a filing with the SEC, which can be accessed through this link. The sale was made to cover tax withholding obligations related to the vesting of equity awards. Also, Director Michael R. Hayden bought 5,000 shares of Ionis Pharmaceuticals stock in a transaction that occurred on Tuesday, November 10th. The shares were bought at an average cost of $29.64 per share, with a total value of $148,200.00. Following the acquisition, the director directly owned 27,000 shares in the company, valued at $800,280. This trade represents a 22.73% increase in their position. The disclosure for this purchase is available in the SEC filing. 1.81% of the stock is owned by insiders.

Ionis Pharmaceuticals Company Profile

(Get Free Report)

Ionis Pharmaceuticals is a biotechnology company that discovers and develops RNA-targeted medicines, with a focus on antisense oligonucleotides. Its medicines are designed to act on RNA and change the production of proteins linked to disease. The company’s research and development programs span neurological, cardiovascular, metabolic and rare diseases. Ionis has developed medicines that it commercializes itself and products advanced or marketed with pharmaceutical partners. Its medicines and partnered products include treatments for conditions such as spinal muscular atrophy and transthyretin amyloidosis.

Read More

Earnings History and Estimates for Ionis Pharmaceuticals (NASDAQ:IONS)

Receive News & Ratings for Ionis Pharmaceuticals Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Ionis Pharmaceuticals and related companies with MarketBeat.com's FREE daily email newsletter.